This week, we’re celebrating a decade of helping life sciences innovators protect their groundbreaking IP. We are grateful for every client and team member who’s been part of this journey. To Our Clients Thank you for trusting us with your breakthrough technologies. Your innovations inspire us every day. To Our Lean, Mean DHL Dream Team: Mike Mand, JD, PhD – 9 DHL years: A powerhouse blend of legal acumen and deep biotech insight Vasanth Vaidyanathan, PhD – 4 DHL years: Inter

SUMMARY Costs for prosecuting patents at the USPTO are set to increase on 1/19/25 Across-the-board 7.5% increase in fees Some targeted fees increase more Some new fees added After-Final 2.0 program terminated as part of fee increase changes Still possible that someone will file a lawsuit to delay Implementation of the fee increases so the future Trump-appointed USPTO Director can reconsider them What new fees/increases are most relevant to biotech companies? Noteworthy is the

A day to celebrate biotech! 🥳 Congrats to Vertex and CRISPR Therapeutics on FDA approval of CASGEVY • 1st product that uses gene editing (See Exa-cel below for more info) And Bluebird for FDA approval yesterday of Lyfgenia • another autologous stem cell-based gene therapy to treat Sickle cell disease Interesting that both were approved on a single-arm (no control arm) trial, as the FDA is more willing to accept this data for a rare genetic disease with a high unmet need, and

DHL is excited to announce the launch of the new doublehelixlaw.com. The new site more clearly conveys info about our high-quality, innovative, non-traditional life sciences patent law firm. We take on less overhead to fit more time building our client's patent portfolios into their IP budget. Check out the new doublehelixlaw.com. About DHL Double Helix Law (DHL) has decades of experience building strong patent portfolios for life science companies. Learn more about DHL and m